Arianna Maiorana

Dr. Arianna Maiorana

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SMSebene Mayorandan
Sebene Mayorandan
UMUta Meyer
Uta Meyer
GGGülden Gokcay
Gülden Gokcay
NSNuria Garcia Segarra
Nuria Garcia Segarra
HBHélène Ogier de Baulny
Hélène Ogier de Baulny
ADAnibh Das
Anibh Das
Hepatorenal tyrosinaemia (Tyr 1) is a rare inborn error of tyrosine metabolism. Without treatment, patients are at high risk of developing acute liver failure, renal dysfunction and in the long run hepatocellular carcinoma. The aim of our study was to collect cross-sectional data.

1 September 2009 in Pediatrics
Verified
Journal Article
Closed access
PDF file
AMArianna Maiorana
Arianna Maiorana
SCstefano cianfarani
stefano cianfarani
CONTEXT: Use of growth hormone (GH) therapy to promote growth in short children born small for gestational age (SGA) was recently approved in the United States and Europe, but there is still disagreement about the magnitude of effectiveness of GH.

1 March 2004 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SCstefano cianfarani
stefano cianfarani
CMChiara Martinez
Chiara Martinez
AMArianna Maiorana
Arianna Maiorana
GSGiuseppe Scirè
Giuseppe Scirè
GSGian Luigi Spadoni
Gian Luigi Spadoni
SBSergio Boemi
Sergio Boemi
Adiponectin is an adipocytokine with insulin-sensitizing and antiatherogenic properties. Reduced concentrations of adiponectin precede the onset of type 2 diabetes and the development of atherosclerosis. Our aim was to quantify adiponectin concentrations in small for gestational age (SGA) children. Fifty-one SGA children, 24 obese, and 17 short-normal children with birth weight appropriate for gestational age (short-AGA) were studied. The statures of the SGA children were corrected for their midparental height and subdivided into two groups according to their corrected height: catch-up growth group, children with corrected height of 0 z-score or greater (n = 17); and noncatch-up growth group, subjects with corrected height less than 0 z-score (n = 34). SGA children showed adiponectin levels significantly lower than short- normal children (35.2 +/- 3.5 vs. 80.4 +/- 26.6 micro g/ml; P < 0.0001) and obese children (77.5 +/- 39.4 micro g/ml; P < 0.0001). Catch-up growth children showed adiponectin levels significantly lower than noncatch-up growth subjects (29.4 +/- 10.3 vs. 38.1 +/- 11.5 micro g/ml; P = 0.01). Adiponectin concentrations were inversely related to height z-score, corrected stature, weight, and body mass index and were positively related to birth weight. Our results suggest that adiponectin levels are reduced in SGA children and are even lower in those with postnatal catch-up growth. Whether this finding implies a higher risk of developing type 2 diabetes and atherosclerosis remains to be established.

1 June 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SCstefano cianfarani
stefano cianfarani
AMArianna Maiorana
Arianna Maiorana
CGCaterina Geremia
Caterina Geremia
GSGiuseppe Scirè
Giuseppe Scirè
GSGian Luigi Spadoni
Gian Luigi Spadoni
DGDaniela Germani
Daniela Germani
Fetal growth restriction is associated with an increased risk of developing insulin resistance and type 2 diabetes in adulthood. In addition, 10-20% of children born small for gestational age (SGA) do not achieve a normal final height. The purpose of this study was to investigate insulin sensitivity and endocrine status in SGA children, compared with that in children born appropriate for gestational age (AGA). Furthermore, within the SGA group, we aimed to relate postnatal growth to anthropometric, biochemical, and endocrine parameters. Eighty-two SGA children (with a mean age of 8.6 +/- 3.5 yr) and 53 short-AGA children (with a mean age of 9.3 +/- 3.3 yr) were studied. A case-control study was carried out in 26 SGA and 26 short-AGA subjects. For each SGA subject, we selected a short-AGA child matched for sex, age (within 1 yr), pubertal status, body mass index (within 0.5 kg/m(2)), and height (within 0.25 z-score). Children's statures were corrected for their midparental height, and SGA children were subdivided into 2 groups: catch-up growth (CG) group (children with corrected height with at least 0 z-score); and non-CG (NCG) group (subjects with corrected height with less than 0 z-score). Comparing SGA with short-AGA subjects, no significant differences in fasting insulin, fasting glucose/insulin ratio, homeostasis assessment model for insulin resistance, and homeostasis assessment model-beta-cell values were observed. SGA children showed significantly reduced levels of glucose (4.4 +/- 0.6 vs. 4.9 +/- 0.6 mM, P < 0.0001), total cholesterol (160.1 +/- 28.8 vs. 171.8 +/- 28.5 mg/dl, P = 0.02), and high-density-lipoprotein cholesterol (53.3 +/- 12.1 vs. 58 +/- 11.4 mg/dl, P = 0.02). The analysis of the subjects selected for the case-control study confirmed that SGA children did not have significant differences in the indices of insulin sensitivity but showed significantly lower glucose levels (4.4 +/- 0.7 vs. 4.9 +/- 0.4 mM, P < 0.005). Subdividing the SGA group into CG (n = 25) and NCG (n = 57) children, we found that NCG children showed significantly higher levels of TSH (2.5 +/- 1.3 vs. 1.9 +/- 0.6 mU/liter, P = 0.002). Our data indicate that SGA children do not have altered insulin sensitivity when compared with auxologically identical AGA subjects but show a significant reduction of glucose concentrations. Whether the lower glucose levels are attributable to an early phase of augmented insulin sensitivity, as previously reported in animal models, has to be established. The finding of higher TSH concentrations in SGA children with blunted CG suggests that intrauterine reprogramming might involve thyroid function, which, in turn, might affect postnatal growth and cholesterol metabolism, eventually increasing the risk of cardiovascular disease.

1 September 2014 in Mitochondrion
Verified
Journal Article
Closed access
RCRosalba Carrozzo
Rosalba Carrozzo
ATAlessandra Torraco
Alessandra Torraco
GFGiuseppe Fiermonte
Giuseppe Fiermonte
DMDiego Martinelli
Diego Martinelli
MNMichela Di Nottia
Michela Di Nottia
CDCarlo Dionisi-Vici
Carlo Dionisi-Vici

15 September 2010 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
AMArianna Maiorana
Arianna Maiorana
VNValerio Nobili
Valerio Nobili
SCSebastiano Calandra
Sebastiano Calandra
PFPaola Francalanci
Paola Francalanci
SBSilvia Bernabei
Silvia Bernabei
ABAndrea Bartuli
Andrea Bartuli